Logo image of SNCE

SCIENCE 37 HOLDINGS INC (SNCE) Stock Price, Forecast & Analysis

USA - Nasdaq - NASDAQ:SNCE - US8086442071 - Common Stock

5.75 USD
+0.02 (+0.35%)
Last: 3/11/2024, 6:05:35 PM
5.7203 USD
-0.03 (-0.52%)
After Hours: 3/11/2024, 6:05:35 PM

SNCE Key Statistics, Chart & Performance

Key Statistics
Market Cap34.67M
Revenue(TTM)60.27M
Net Income(TTM)-124.65M
Shares6.03M
Float5.01M
52 Week High12.96
52 Week Low3.73
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-7.26
PEN/A
Fwd PEN/A
Earnings (Next)05-13 2024-05-13/bmo
IPO2020-11-20
Sector
GICS SectorHealth Care
GICS IndustryLife Sciences Tools & Services
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences


SNCE short term performance overview.The bars show the price performance of SNCE in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 -5 10 -10

SNCE long term performance overview.The bars show the price performance of SNCE in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of SNCE is 5.75 USD. In the past month the price increased by 1.23%. In the past year, price decreased by -19.47%.

SCIENCE 37 HOLDINGS INC / SNCE Daily stock chart

SNCE Competitors/Peers

The largest stocks on the US markets in the "Life Sciences Tools & Services" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
TMO THERMO FISHER SCIENTIFIC INC 25.85 217.58B
DHR DANAHER CORP 30.02 163.50B
BRKRP BRUKER CORP - BRKR 6 3/8 09/01/28 185.88 56.48B
A AGILENT TECHNOLOGIES INC 24.79 39.21B
IQV IQVIA HOLDINGS INC 19.43 38.49B
MTD METTLER-TOLEDO INTERNATIONAL 33.87 28.95B
WAT WATERS CORP 30.3 22.91B
ILMN ILLUMINA INC 31.04 20.68B
WST WEST PHARMACEUTICAL SERVICES 39.13 19.90B
MEDP MEDPACE HOLDINGS INC 39.99 16.11B
TEM TEMPUS AI INC N/A 11.43B
RVTY REVVITY INC 20.2 10.97B

About SNCE

Company Profile

SNCE logo image Science 37 Holdings Inc is a US-based company operating in Life Sciences Tools & Services industry. The company is headquartered in Research Triangle Park, North Carolina and currently employs 460 full-time employees. The company went IPO on 2020-11-20. Science 37 Holdings, Inc. is engaged in patient-centric clinical trials and in supporting novel approaches to decentralized clinical trial designs. Through its patient-centric approach, it reduces the impact of the geographic barriers associated with conventional physical clinical trial sites, enabling recruitment of virtually any patient. Its offerings lie in its configurable unified technology platform combined with its centralized patient recruitment capabilities and specialized network of patient communities. Its unified technology platform is purpose-built for patient-centric clinical trial execution and is designed to provide an end-to-end, single stop solution. The company also provides specialized networks of patient communities, telemedicine investigators, mobile nurses, and remote coordinators designed for the purpose of orchestrating patient-centric clinical trials. The company uses diversified, multi-channel programs to identify patients who fit the profile for each of its projects.

Company Info

SCIENCE 37 HOLDINGS INC

800 Park Offices Drive, Suite 3606

RESEARCH TRIANGLE PARK NORTH CAROLINA US

CEO: Andrew McDonald

Employees: 460

SNCE Company Website

Phone: 19843773737

SCIENCE 37 HOLDINGS INC / SNCE FAQ

What does SNCE do?

Science 37 Holdings Inc is a US-based company operating in Life Sciences Tools & Services industry. The company is headquartered in Research Triangle Park, North Carolina and currently employs 460 full-time employees. The company went IPO on 2020-11-20. Science 37 Holdings, Inc. is engaged in patient-centric clinical trials and in supporting novel approaches to decentralized clinical trial designs. Through its patient-centric approach, it reduces the impact of the geographic barriers associated with conventional physical clinical trial sites, enabling recruitment of virtually any patient. Its offerings lie in its configurable unified technology platform combined with its centralized patient recruitment capabilities and specialized network of patient communities. Its unified technology platform is purpose-built for patient-centric clinical trial execution and is designed to provide an end-to-end, single stop solution. The company also provides specialized networks of patient communities, telemedicine investigators, mobile nurses, and remote coordinators designed for the purpose of orchestrating patient-centric clinical trials. The company uses diversified, multi-channel programs to identify patients who fit the profile for each of its projects.


What is the stock price of SCIENCE 37 HOLDINGS INC today?

The current stock price of SNCE is 5.75 USD. The price increased by 0.35% in the last trading session.


What is the dividend status of SCIENCE 37 HOLDINGS INC?

SNCE does not pay a dividend.


What is the ChartMill rating of SCIENCE 37 HOLDINGS INC stock?

SNCE has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


Where is SCIENCE 37 HOLDINGS INC (SNCE) stock traded?

SNCE stock is listed on the Nasdaq exchange.


Can you provide the market cap for SCIENCE 37 HOLDINGS INC?

SCIENCE 37 HOLDINGS INC (SNCE) has a market capitalization of 34.67M USD. This makes SNCE a Nano Cap stock.


SNCE Technical Analysis

ChartMill assigns a technical rating of 4 / 10 to SNCE. When comparing the yearly performance of all stocks, SNCE is a bad performer in the overall market: 70.82% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

SNCE Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to SNCE. SNCE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

SNCE Financial Highlights

Over the last trailing twelve months SNCE reported a non-GAAP Earnings per Share(EPS) of -7.26. The EPS decreased by -881.08% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -164.66%
ROE -241.1%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-429.41%
Sales Q2Q%-8.37%
EPS 1Y (TTM)-881.08%
Revenue 1Y (TTM)-19.21%

SNCE Forecast & Estimates

10 analysts have analysed SNCE and the average price target is 14.11 USD. This implies a price increase of 145.39% is expected in the next year compared to the current price of 5.75.

For the next year, analysts expect an EPS growth of -72.66% and a revenue growth -14.69% for SNCE


Analysts
Analysts76
Price Target14.11 (145.39%)
EPS Next Y-72.66%
Revenue Next Year-14.69%

SNCE Ownership

Ownership
Inst Owners0.02%
Ins Owners287.18%
Short Float %N/A
Short RatioN/A